We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+5.28%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$5.14B
AUM Growth
+$467M
(+10%)
Cap. Flow
+$273M
Cap. Flow
% of AUM
5.31%
Top 10 Holdings %
Top 10 Hldgs %
11.46%
Holding
1,074
New
159
Increased
412
Reduced
333
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$28.6M |
| 2 |
AGN
Allergan plc
AGN
|
+$26.5M |
| 3 |
Toro Company
TTC
|
+$22.4M |
| 4 |
PepsiCo
PEP
|
+$20.4M |
| 5 |
Lockheed Martin
LMT
|
+$17.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$26.1M |
| 2 |
Wells Fargo
WFC
|
+$19.4M |
| 3 |
Centene
CNC
|
+$17.3M |
| 4 |
Eli Lilly
LLY
|
+$15.8M |
| 5 |
Kroger
KR
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Financials | 18.08% |
| 3 | Industrials | 12.96% |
| 4 | Healthcare | 11.05% |
| 5 | Consumer Discretionary | 11.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
P
726
Everpure Inc
P
$24.8B
| $440K | 0.01% |
+27,520
| New | +$377K |
|
727
Scansource
SCSC
$1.12B
| $440K | 0.01% |
10,090
-6,077
| -38% | -$239K |
|
|
SPNE
728
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $440K | 0.01% |
39,213
+9,937
| +34% | +$115K |
|
729
BioMarin Pharmaceuticals
BMRN
$11.5B
| $435K | 0.01% |
+4,670
| New | +$413K |
|
730
Akebia Therapeutics
AKBA
$327M
| $429K | 0.01% |
21,790
+2,310
| +12% | +$35.5K |
|
|
RUTH
731
DELISTED
Ruth's Hospitality Group, Inc.
RUTH
| $427K | 0.01% |
20,401
| – | – |
|
732
Box
BOX
$4.02B
| $423K | 0.01% |
+21,910
| New | +$412K |
|
|
TVPT
733
DELISTED
Travelport Worldwide Limited
TVPT
| $412K | 0.01% |
26,239
+150
| +0.6% | +$2.19K |
|
|
MRLN
734
DELISTED
Marlin Business Services Corp
MRLN
| $409K | 0.01% |
14,240
+6,070
| +74% | +$159K |
|
735
Ingles Markets
IMKTA
$1.63B
| $406K | 0.01% |
+15,780
| New | +$421K |
|
|
CDTX
736
DELISTED
Cidara Therapeutics
CDTX
| $405K | 0.01% |
2,503
-705
| -22% | -$100K |
|
737
Lineage Cell Therapeutics
LCTX
$257M
| $403K | 0.01% |
162,023
+30,568
| +23% | +$75.8K |
|
|
PCMI
738
DELISTED
PCM, Inc
PCMI
| $401K | 0.01% |
28,658
-7,880
| -22% | -$116K |
|
|
NPKI
739
NPK International
NPKI
$1.21B
| $398K | 0.01% |
+39,800
| New | +$326K |
|
740
Strategic Education
STRA
$1.71B
| $396K | 0.01% |
4,540
-1,230
| -21% | -$103K |
|
741
Consolidated Edison
ED
$41.6B
| $395K | 0.01% |
4,890
-400
| -8% | -$33.1K |
|
742
PC Connection
CNXN
$2.05B
| $388K | 0.01% |
13,760
-9,850
| -42% | -$256K |
|
743
Sierra Bancorp
BSRR
$548M
| $386K | 0.01% |
14,200
-1,500
| -10% | -$38.2K |
|
|
BELFB
744
Bel Fuse Inc Class B
BELFB
$3.88B
| $385K | 0.01% |
12,351
-1,500
| -11% | -$39.6K |
|
|
EVRI
745
DELISTED
Everi Holdings
EVRI
| $385K | 0.01% |
50,730
-176,197
| -78% | -$1.32M |
|
746
Corcept Therapeutics
CORT
$10.2B
| $382K | 0.01% |
+19,810
| New | +$295K |
|
747
American Public Education
APEI
$875M
| $381K | 0.01% |
+18,100
| New | +$368K |
|
748
Conagra Brands
CAG
$7.07B
| $380K | 0.01% |
11,250
| – | – |
|
|
PTLA
749
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $376K | 0.01% |
6,950
-8,260
| -54% | -$485K |
|
|
TLRA
750
DELISTED
Telaria, Inc.
TLRA
| $365K | 0.01% |
83,705
-4,300
| -5% | -$12.5K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2017 Portfolio in Review
As of Q3 2017, Jacobs Levy Equity Management held 1,074 positions worth $5.14B, up 10% from $4.68B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jacobs Levy Equity Management deployed $273M of net new capital in Q3 2017, opening 159 new positions and adding to 412 existing holdings. Its largest new stake was Allergan plc: 114,141 shares worth $23.4M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Intuit, an estimated $26.1M trimmed.
- Jacobs Levy Equity Management's largest Q3 2017 buy was Allergan plc: 114,141 shares worth $23.4M.
- Jacobs Levy Equity Management added most to Philip Morris in Q3 2017, an estimated $28.6M increase.
- Jacobs Levy Equity Management's biggest Q3 2017 reduction was Intuit, cutting an estimated $26.1M.
- Jacobs Levy Equity Management fully exited BWX Technologies in Q3 2017, selling an estimated $13.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 11% of its $5.14B portfolio in Q3 2017.
- Jacobs Levy Equity Management opened 159 new positions and closed 136 in Q3 2017.
- Jacobs Levy Equity Management's portfolio value rose 10% quarter-over-quarter to $5.14B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2017, filed 14 Nov 2017.